242 related articles for article (PubMed ID: 24735925)
1. Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4.
Liu H; Westergard TD; Cashen A; Piwnica-Worms DR; Kunkle L; Vij R; Pham CG; DiPersio J; Cheng EH; Hsieh JJ
Cancer Cell; 2014 Apr; 25(4):530-42. PubMed ID: 24735925
[TBL] [Abstract][Full Text] [Related]
2. AF4 and AF4-MLL mediate transcriptional elongation of 5-lipoxygenase mRNA by 1, 25-dihydroxyvitamin D3.
Ahmad K; Scholz B; Capelo R; Schweighöfer I; Kahnt AS; Marschalek R; Steinhilber D
Oncotarget; 2015 Sep; 6(28):25784-800. PubMed ID: 26329759
[TBL] [Abstract][Full Text] [Related]
3. Harnessing the hidden antitumor power of the MLL-AF4 oncogene to fight leukemia.
Matkar S; Katona BW; Hua X
Cancer Cell; 2014 Apr; 25(4):411-3. PubMed ID: 24735921
[TBL] [Abstract][Full Text] [Related]
4. The heterodimerization domains of MLL-FYRN and FYRC--are potential target structures in t(4;11) leukemia.
Pless B; Oehm C; Knauer S; Stauber RH; Dingermann T; Marschalek R
Leukemia; 2011 Apr; 25(4):663-70. PubMed ID: 21233834
[TBL] [Abstract][Full Text] [Related]
5. Restoring MLL reactivates latent tumor suppression-mediated vulnerability to proteasome inhibitors.
Ge M; Li D; Qiao Z; Sun Y; Kang T; Zhu S; Wang S; Xiao H; Zhao C; Shen S; Xu Z; Liu H
Oncogene; 2020 Sep; 39(36):5888-5901. PubMed ID: 32733069
[TBL] [Abstract][Full Text] [Related]
6. Leukemic fusion genes MLL/AF4 and AML1/MTG8 support leukemic self-renewal by controlling expression of the telomerase subunit TERT.
Gessner A; Thomas M; Castro PG; Büchler L; Scholz A; Brümmendorf TH; Soria NM; Vormoor J; Greil J; Heidenreich O
Leukemia; 2010 Oct; 24(10):1751-9. PubMed ID: 20686504
[TBL] [Abstract][Full Text] [Related]
7. t(4;11) leukemias display addiction to MLL-AF4 but not to AF4-MLL.
Kumar AR; Yao Q; Li Q; Sam TA; Kersey JH
Leuk Res; 2011 Mar; 35(3):305-9. PubMed ID: 20869771
[TBL] [Abstract][Full Text] [Related]
8. Expression of MLL-AF4 or AF4-MLL fusions does not impact the efficiency of DNA damage repair.
Castaño J; Herrero AB; Bursen A; González F; Marschalek R; Gutiérrez NC; Menendez P
Oncotarget; 2016 May; 7(21):30440-52. PubMed ID: 27119507
[TBL] [Abstract][Full Text] [Related]
9. A human fetal liver-derived infant MLL-AF4 acute lymphoblastic leukemia model reveals a distinct fetal gene expression program.
Rice S; Jackson T; Crump NT; Fordham N; Elliott N; O'Byrne S; Fanego MDML; Addy D; Crabb T; Dryden C; Inglott S; Ladon D; Wright G; Bartram J; Ancliff P; Mead AJ; Halsey C; Roberts I; Milne TA; Roy A
Nat Commun; 2021 Nov; 12(1):6905. PubMed ID: 34824279
[TBL] [Abstract][Full Text] [Related]
10. Crosstalk between 14-3-3θ and AF4 enhances MLL-AF4 activity and promotes leukemia cell proliferation.
Fioretti T; Cevenini A; Zanobio M; Raia M; Sarnataro D; Salvatore F; Esposito G
Cell Oncol (Dordr); 2019 Dec; 42(6):829-845. PubMed ID: 31493143
[TBL] [Abstract][Full Text] [Related]
11. Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL-AF4 fusion protein.
Jenkins TW; Downey-Kopyscinski SL; Fields JL; Rahme GJ; Colley WC; Israel MA; Maksimenko AV; Fiering SN; Kisselev AF
Sci Rep; 2021 May; 11(1):10883. PubMed ID: 34035431
[TBL] [Abstract][Full Text] [Related]
12. The AF4.MLL fusion protein is capable of inducing ALL in mice without requirement of MLL.AF4.
Bursen A; Schwabe K; Rüster B; Henschler R; Ruthardt M; Dingermann T; Marschalek R
Blood; 2010 Apr; 115(17):3570-9. PubMed ID: 20194896
[TBL] [Abstract][Full Text] [Related]
13. miR-130b and miR-128a are essential lineage-specific codrivers of t(4;11) MLL-AF4 acute leukemia.
Malouf C; Antunes ETB; O'Dwyer M; Jakobczyk H; Sahm F; Landua SL; Anderson RA; Soufi A; Halsey C; Ottersbach K
Blood; 2021 Nov; 138(21):2066-2092. PubMed ID: 34111240
[TBL] [Abstract][Full Text] [Related]
14. Evidence-based RT-PCR methods for the detection of the 8 most common MLL aberrations in acute leukemias.
Burmeister T; Meyer C; Gröger D; Hofmann J; Marschalek R
Leuk Res; 2015 Feb; 39(2):242-7. PubMed ID: 25510485
[TBL] [Abstract][Full Text] [Related]
15. MLL leukemia and future treatment strategies.
Marschalek R
Arch Pharm (Weinheim); 2015 Apr; 348(4):221-8. PubMed ID: 25740345
[TBL] [Abstract][Full Text] [Related]
16. CDKN1A-mediated responsiveness of MLL-AF4-positive acute lymphoblastic leukemia to Aurora kinase-A inhibitors.
Chen YP; Lin HJ; Chen JS; Tsai MY; Hsieh HP; Chang JY; Chen NF; Chang KC; Huang WT; Su WC; Yang ST; Chang WC; Hung LY; Chen TY
Int J Cancer; 2014 Aug; 135(3):751-62. PubMed ID: 24382688
[TBL] [Abstract][Full Text] [Related]
17. Development of embryonic and adult leukemia mouse models driven by MLL-ENL translocation.
Sinha R; Porcheri C; d'Altri T; González J; Ruiz-Herguido C; Rabbitts T; Espinosa L; Bigas A
Exp Hematol; 2020 May; 85():13-19. PubMed ID: 32437911
[TBL] [Abstract][Full Text] [Related]
18. Instructive Role of MLL-Fusion Proteins Revealed by a Model of t(4;11) Pro-B Acute Lymphoblastic Leukemia.
Lin S; Luo RT; Ptasinska A; Kerry J; Assi SA; Wunderlich M; Imamura T; Kaberlein JJ; Rayes A; Althoff MJ; Anastasi J; O'Brien MM; Meetei AR; Milne TA; Bonifer C; Mulloy JC; Thirman MJ
Cancer Cell; 2016 Nov; 30(5):737-749. PubMed ID: 27846391
[TBL] [Abstract][Full Text] [Related]
19. Targeting MLL-AF4 with short interfering RNAs inhibits clonogenicity and engraftment of t(4;11)-positive human leukemic cells.
Thomas M; Gessner A; Vornlocher HP; Hadwiger P; Greil J; Heidenreich O
Blood; 2005 Nov; 106(10):3559-66. PubMed ID: 16046533
[TBL] [Abstract][Full Text] [Related]
20. Frat2 mediates the oncogenic activation of Rac by MLL fusions.
Walf-Vorderwülbecke V; de Boer J; Horton SJ; van Amerongen R; Proost N; Berns A; Williams O
Blood; 2012 Dec; 120(24):4819-28. PubMed ID: 23074275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
